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Abstract
Introduction: The inhibition of estrogen receptor (ER) a action with the ER antagonist tamoxifen is an established
treatment in the majority of breast cancers. De novo or acquired resistance to this therapy is common. Expression
of ERb in breast tumors has been implicated as an indicator of tamoxifen sensitivity. The mechanisms behind this
observation remain largely uncharacterized. In the present study, we investigated whether ERb can modulate
pathways implicated in endocrine resistance development.
Methods: T47-D and MCF-7 ERa-expressing breast cancer cells with tetracycline-regulated expression of ERb were
used as a model system. Expression levels and activity of known regulators of endocrine resistance were analyzed
by performing quantitative polymerase chain reaction assays, Western blot analysis and immunostaining, and
sensitivity to tamoxifen was investigated by using a cell proliferation kit.
Results: Expression of ERb in ERa-positive T47-D and MCF-7 human breast cancer cells resulted in a decrease in
Akt signaling. The active form of an upstream regulator of Akt, proto-oncogene c-ErbB-2/receptor tyrosine kinase
erbB-3 (HER2/HER3) receptor dimer, was also downregulated by ERb. Furthermore, ERb increased expression of the
important inhibitor of Akt, phosphatase and tensin homologue deleted on chromosome 10 (PTEN). Importantly,
ERb expression increased the sensitivity of these breast cancer cells to tamoxifen.
Conclusions: Our results suggest a link between expression of ERb and endocrine sensitivity by increasing PTEN
levels and decreasing HER2/HER3 signaling, thereby reducing Akt signaling with subsequent effects on
proliferation, survival and tamoxifen sensitivity of breast cancer cells. This study supports initiatives to further
investigate whether ERb presence in breast cancer samples is an indicator for endocrine response. Current
therapies in ERa-positive breast cancers aim to impair ERa activity with antagonists or by removal of endogenous
estrogens with aromatase inhibitors. Data from this study could be taken as indicative for also using ERb as a
target in selected groups of breast cancer.
Introduction
Approximately two-thirds of breast cancers express
estrogen receptors (ERs) and initially require estrogen to
grow, and are therefore treated with ER antagonists,
such as tamoxifen, or by depletion of endogenous estro-
gens with aromatase inhibitors [1,2]. Two ERs, ERa and
ERb, have been identified [3]. ERa plays an important
role in the proliferation and progression of breast can-
cer, whereas a distinct function of ERb in breast cancer
initiation and development has not yet been clearly
established. In in vitro settings, ERb inhibits prolifera-
tion, migration and invasion of breast cancers cells [4-9]
as well as the growth of breast tumor xenografts [10].
ERa is the marker of choice to decide endocrine treat-
ment of breast cancer. However, in the case of tamoxi-
fen treatment, despite the initial response to the
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even though their ERa status may remain unchanged
[11]. ERb has also been considered a marker of endo-
crine response. Lower expression of ERb is found in
tamoxifen-resistant tumors, and high levels of ERb are
sometimes associated with a better clinical outcome in
ERa-expressing breast tumors [12]. However, some stu-
dies have indicated that in high-grade, ERa-negative,
node-positive breast tumors, ERb presence appears to
be a marker related to a more aggressive breast cancer
[13].
Breast tumors overexpressing receptor tyrosine kinases
(RTKs) are less likely to benefit from tamoxifen treat-
ment [14-17]. Receptor tyrosine protein kinase erbB-3
(HER3) and proto-oncogene c-ErbB-2 (HER2) are mem-
bers of the epidermal growth factor receptor (EGFR)
family. HER3 lacks intrinsic kinase activity and relies on
heterodimerization with other members of the EGFR
family for transduction of signals. There is growing
awareness of the importance of HER2/HER3 heterodi-
mer formation in breast cancer progression, where coex-
pression of HER2 and HER3 has been shown to be a
poor prognostic indicator associated with resistance to
endocrine therapy and to HER tyrosine kinase inhibitors
[18-22]. The majority of HER2-positive tumors are
strongly positive for HER3 [18], which is also seen in
mouse models of breast cancers, where high expression
of HER2 is commonly associated with activated and
overexpressed HER3 [23]. Furthermore, inhibition of
HER2 correlates with reduction in HER3 phosphoryla-
tion [24] and, correspondingly, inhibition of HER3
reduces phosphorylation of HER2 and abrogates HER2-
mediated tamoxifen resistance [25].
Phosphatidylinositol 3-kinase (PI3K) promotes genera-
tion of phosphatidylinositol (3,4,5)-triphosphate (PIP3),
which leads to phosphorylation and activation of the
serine/threonine kinase Akt. The PI3K/Akt pathway
plays important roles in regulating cell proliferation,
growth, apoptosis and motility. Increased activity due to
genetic changes is frequently seen in breast cancer,
resulting in tumor progression, metastases and resis-
tance to endocrine treatment [26-29]. Mutation of the
PIK3CA gene, which encodes the p110a catalytic subu-
nit of PI3K, leads to activation of Akt and is found in
18% to 40% of human breast cancers [30-32]. Stimula-
tion of RTKs also activates Akt [33-35], and overexpres-
sion of HER2 is linked to elevated Akt activities [36-38].
In ERa-positive breast cancers treated with tamoxifen,
detection of activated Akt at diagnosis has been shown
to correlate to decreased overall survival [39].
Constitutive active Akt is also associated with loss of
phosphatase and tensin homologue deleted on chromo-
some 10 (PTEN) expression [40]. PTEN is a tumor sup-
pressor whose expression is often lost in breast cancers
and associated with poor disease outcome [41-44].
PTEN antagonizes PI3K activity by dephosphorylating
PIP3, resulting in lower levels of active Akt [45].
The goal of this study was to investigate whether
ERb1 (referred to hereinafter as ERb) has any effect on
the RTK/PI3K/Akt signaling pathway and thereby repre-
sents a regulator of tamoxifen sensitivity. We show that
in ERa-positive breast cancer cells, expression of ERb
reduced Akt activation through downregulation of
HER2/HER3 signaling and upregulation of PTEN and,
importantly, increased sensitivity to tamoxifen. ERb has
sometimes been suggested as a predictor of endocrine
response; however, the mechanisms underlying this
response are still unknown. Here we suggest a link
between expression of ERb and endocrine sensitivity.
Materials and methods
Cell cultures
T47-D cells with tetracycline-regulated expression of
ERb485 (T47-DERb) [4] were routinely grown not
expressing ERb (-ERb) in RPMI 1640 medium (Invitro-
gen, Paisley, United Kingdom) supplemented with 5%
heat-inactivated fetal bovine serum (FBS) (Invitrogen),
1% penicillin-streptomycin (Invitrogen) and 10 ng/mL
doxycycline (Sigma, Stockholm, Sweden). For experi-
ments, cells were grown for 24 to 168 hours prior to
analysis in phenol red-free RPMI 1640 medium supple-
mented with 2% heat-inactivated FBS, 1% penicillin-
streptomycin, 10 ng/mL -ERb or 0.01 ng/mL doxycy-
cline +ERb in the presence of vehicle alone, ethanol
and/or dimethyl sulfoxide (Sigma), or in 10 nM 2,3-bis
(4-hydroxy-phenyl)-propionitrile (DPN) (Tocris, Bristol,
United Kingdom), 10 nM 4,4’,4"-(4-propyl-[1H]-pyra-
zole-1,3,5-triyl)trisphenol (PPT) (Tocris), 10 nM 17b-
estradiol (E2) (Sigma), 10 nM 7-bromo-2-(4-hydroxy-
phenyl)-1,3-benzoxazol-5-ol (WAY) (Tocris), 100 nM
ICI 182, 789 (ICI) (Tocris) or 100 to 1,000 nM 4-
hydroxy-tamoxifen (4-OH-T) (Sigma). MCF-7 breast
cancer cells with tetracycline-regulated expression of
ERb485 were treated in a similar manner. T47-DPBI
cells (Mock) were used as controls.
Quantitative real-time polymerase chain reaction assays
Cells were grown in six-well tissue culture plates for 24
to 96 hours and lysed in TRIzol reagent (Invitrogen),
then RNA was extracted and cDNA was synthesized as
described previously [46]. Quantitative real-time poly-
merase reaction assays (qRT-PCR) were performed with
SYBR Green PCR Master Mix in an ABI PRISM 7500
(Applied Biosystems, Foster City, USA). The following
primers were used: 18S forward 5’-CCTGCGGCTTAA-
TTTGACTCA-3’, reverse 5’-AGCTATCAATCTGT-
CAATCCTGTCC-3’; ERb forward 5’-ACTTGCTG-
AACGCCGTGACC-3’,r e v e r s e5 ’-CAGATGTTCCA-
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GACTCTCTCC-3’, reverse 5’-CAAGTACTCGGGG-
TTCTCCA-3’; HER3 forward 5’-GTCATGAGGGCG-
AACGAC-3’,r e v e r s e5 ’-AGAGTCCCAGGACAC-
ACTGC-3’;a n dPTEN forward 5’-GGGGAAGTAAG-
GACCAGAGAC-3’, reverse 5’-TCCAGATGATTCTT-
TAACAGGTAGC-3’. Quantification was carried out fol-
lowing the supplier’s protocols using the standard curve
method.
Whole-cell extracts
Cells grown on plates were washed with ice-cold phos-
phate-buffered saline (PBS), transferred to Eppendorf
tubes and pelleted by centrifugation. Cell pellets were
freeze-thawed and resuspended with PBS-TDS buffer
(PBS with 1% Triton X-100, 0.5% sodium deoxycholate,
0.1% sodium dodecyl sulfate (SDS), 1 mM ethylenedia-
minetetraacetic acid and phosphatase inhibitors
(Sigma)), incubated for 30 minutes on ice and centri-
fuged at 11,000 rpm for 10 minutes at 4°C. Supernatants
were collected for further analysis. Protein quantification
was carried out using a bicinchoninic acid protein assay
kit (Pierce Biotechnology, Rockford, USA).
Western blot analysis
Forty micrograms of total cellular protein were separated
using 7.5% SDS-polyacrylamide gel electrophoresis and
electrotransferred onto a nitrocellulose membrane
(Hybond-C; AmershamBuckinghamshire, United King-
dom). After blocking in 5% milk protein (wt/vol) in PBS,
0.1% Tween 20 (vol/vol) membranes were sequentially
incubated with primary and secondary antibodies. The
following antibodies were used: anti-ERb (14021; Abcam,
Cambridge, United Kingdom), GTX110607 (GeneTex,
Irvine, USA), anti-phospho-HER3 tyr1289 (21D3; Cell
Signaling Technology, Danvers, USA), anti-phospho-Akt
pathway sampler kit (9916; Cell Signaling Technology),
anti-phospho-HER2 antibody sampler kit (9923; Cell Sig-
naling Technology), anti-PTEN (26H9; Cell Signaling
Technology); anti-a-tubulin (11H10; Cell Signaling Tech-
nology), anti-EGFR (E12020; Transduction Laboratories,
Franklin Lakes, USA), anti-HER3 (sc-285; Santa Cruz
Biotechnology, Santa Cruz, CA, USA) and anti-b-actin
(Sigma). The secondary antibodies were horseradish per-
oxidase-conjugated (Sigma). Visualization was carried
out using the ECL Plus kit (Amersham) or the Super-
Signal West Pico kit (Pierce Biotechnology). At least
three independent experiments were carried out.
Immunofluorescence
Cells were cultured on sterilized glass coverslips in high-
or low-doxycycline conditions for 4 days as described
above. The cells were fixed by ice-cold methanol and ice-
cold acetone for 10 minutes and 1 minute, respectively.
Blocking of nonspecific binding was done with BlockAce
(Dainippon Pharmaceutical, Osaka, Japan) for 1 h at room
temperature. The samples were then incubated overnight
at 4°C with the following antibodies at the indicated dilu-
tions in 10% BlockAce in PBS: anti-HER2, 1:150 (29D8;
Cell Signaling Technology), and anti-PTEN, 1:100 (26H9;
Cell Signaling Technology). After washes with PBS, sam-
ples were incubated with corresponding Alexa Fluor 568-
conjugated secondary antibody 1:500 (Invitrogen) and
Hoechst 33342 5 μg/mL (Molecular Probes, Eugen, USA)
in PBS for 1 hour at room temperature. Samples were
mounted with VECTASHIELD (Vector Laboratories, Bur-
lingame, USA) after washes with PBS. Negative controls
were incubated without primary antibody. To compare
staining intensity between different samples, pictures were
obtained with fixed exposure time. Staining was repeated
three times to confirm consistent results.
Fluorescence imaging
Pictures of fluorescence staining were captured with a
Zeiss Axioplan 2 microscope using Zeiss Plan-Apochro-
mat 63×/1.40 oil lens (Carl Zeiss, Oberkochen, Ger-
many). Images were acquired with a Zeiss AxioCam
MRm camera under the same settings. Captured images
were processed using the AxioVision Rel 4.6 program
a n de d i t e du s i n gA d o b eP h o t o S h o pC 5 4s o f t w a r e
(Adobe, San Jose, USA), and the same adjustments were
applied to all images.
Cell proliferation
T47-DERb and MCF-7ERb cells were cultured for 3
days in high (-ERb)o rl o w( + E R b) doxycycline concen-
trations in the absence or presence of vehicle, E2 or
WAY. On the third day, cells were replated on 96-well
plates and allowed to adhere for 24 hours. Thereafter
increasing concentrations of 4-OH-T were added.
Growth medium was changed every other day. Cell via-
bility was measured after 0, 5 and 7 days of incubation
with 4-OH-T using a colorimetric assay (WST-1; Roche,
Basel, Switzerland) following the manufacturer’ss u g g e s -
tions. Measurement of absorbance was done using a
SpectraMax 250 microplate reader (Molecular Devices,
Sunnyvale, USA) against a background control as blank.
Statistical analysis
Differences between more than two groups were com-
pared by one-way analysis of variance and Tukey’s mul-
tiple posttest using GraphPad software (GraphPad, San
Diego, USA).
Results and discussion
AKT signaling is repressed by ERb
To assess the effect of ERb on Akt signaling in human
breast cancer cells, ERa-expressing T47-D and MCF-7
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MCF-7ERb, respectively) were grown at inducing condi-
tions for different times, and active Akt as well as the
activity of a downstream target were investigated by
immunoblot analysis. Both cell lines used in the present
study have PIK3CA mutations, H1047R (catalytic
domain) in T47-D and E545K (helical domain) in MCF-
7 cells [47], resulting in active Akt, higher in T47-D, at
low stimulatory conditions. In both cell lines, expression
of ERb clearly downregulated phosphorylated Akt
(pAkt) (Additional file 1). To further analyze the ERb
effect, pAkt levels were assessed throughout 1 to 7 days
(Figure 1A). In T47-DERb cells, levels of pAkt were
clearly downregulated by ERb after 4 and 7 days of ERb
induction (Figure 1A). No additional effect was seen
upon the addition of the selective ERb agonist DPN.
Levels of total Akt protein did not change, indicating
that reduced pAkt levels were due to less phosphoryla-
tion. Downregulation of pAkt was also observed upon
ERb expression in MCF-7ERb cells (Figure 1B), showing
that this is not a unique ERb effect in one selected T47-
D cell clone. Moreover, pAkt levels in the mock cell line
T47-DPBI were not affected by different doxycycline
concentrations (Figure 1C), indicating that levels of
pAkt are influenced not by doxycycline, but by induc-
tion of ERb expression. One downstream target of Akt
is GSK3b. Following ERb expression, pAkt downregula-
tion correlated with reduced levels of phosphorylated
GSK3b (Figure 1A).
Since addition of the ERb ligand DPN exerted no
stable, repeatable additional effect to that already
observed following ERb expression (Figure 1 and 1
data not shown), we investigated whether ER antago-
nists would prevent ERb-induced decrease of Akt
phosphorylation. For this purpose, ICI 182, 780 (ICI), a
selective ER downregulator, and the selective estrogen
modulator 4-OH-T were used. As expected, ICI
induced complete downregulation of ERa (Figure 1D).
ERb protein levels were partially downregulated by ICI,
whereas 4-OH-T had no significant effect on either
ERa or ERb protein levels (Figure 1E). Furthermore,
ERa protein levels were reduced in cells expressing
ERb (Figures 1D and 1E). This latter finding was con-
sistently observed in all inducible systems that we
tested. Treatment with ICI or 4-OH-T did not inhibit
the ERb-induced decrease of pAkt levels. However, in
ICI- or 4-OH-T-treated cells, the ERb-induced
decrease of pAkt levels was less than that in cells not
exposed to ICI or 4-OH-T, suggesting a weak antago-
nistic action of ICI and 4-OH-T. In summary, in two
different ERa-expressing human breast cancer cell
lines, ERb expression clearly reduced activation of the
Akt signaling pathway.
ERb regulation of HER2 and HER3 expression
Members of the EGFR family are potent activators of
the PI3K/Akt pathway, contributing to endocrine resis-
tance in breast tumors. Therefore, we investigated the
effect of ERb expression on EGFR, HER2 and HER3
protein levels in T47-D and MCF-7 cells. Upon ERb
expression, levels of EGFR were unchanged in T47-
DERb cells (Figure 2A). In contrast, ERb expression
upregulated HER2 and downregulated HER3 protein
levels. No further changes were seen with DPN. Treat-
ment of T47-DERb cells expressing ERb or not with the
ERa-selective ligand PPT decreased HER2 protein
expression but had no effect on HER3 protein expres-
sion (Additional file 2). In the control mock cell line
T47-DPBI, the two doxycycline concentrations did not
change HER2 and HER3 protein levels (Figure 2B), sug-
gesting that expression of these two membrane recep-
tors in T47-DERb cells is regulated by ERb and not by
doxycycline. In MCF-7ERb cells, expression of HER2
protein was not clearly upregulated by ERb.H o w e v e r ,
H E R 3p r o t e i ne x p r e s s i o nw a sd o w n r e g u l a t e di nM C F -
7ERb upon ERb expression (Figure 2C), showing that
ERb-induced HER3 downregulation is not seen in only
one isolated cell clone and type. The ERb-induced
increase in HER2 levels was also seen by performing
immunocytochemistry in T47-DERb cells (Figure 2D).
Exposure of cells to ICI or 4-OH-T induced an overall
increase in expression of HER2 protein, and ERb upre-
gulation of HER2 was completely abolished by both ICI
and 4-OH-T, as analyzed after 4 days of ERb expression
(Figure 3A). qPCR analysis showed that in cells not
e x p o s e dt oI C Io r4 - O H - T ,E R b expression increased
HER2 mRNA levels. Upon ICI or 4-OH-T exposure,
HER2 mRNA levels increased, and, in this experimental
setting, ERb decreased HER2 mRNA levels. This was
not clearly related to HER2 protein levels at 4 days of
ERb expression. However, following 7 days of ERb
expression, HER2 protein levels correlated with HER2
mRNA levels seen at 4 days, indicative of slow turnover
of HER2 protein (Figure 3A, bottom). In a recent study,
PAX2 and the ER coactivator AIB1 (SRC-3) were shown
to compete for binding to ERa and regulation of HER2
gene transcription in breast cancer cells [48]. In cells
treated with estrogen or tamoxifen, PAX2 acted together
with ERa as a transcriptional repressor where HER2
mRNA was decreased, whereas HER2 transcription
increased with high levels of SRC-3. Interestingly, we
show here that HER2 mRNA and protein levels were
increased upon ERb expression. E2 treatment or treat-
ment with the ERa-selective ligand PPT of T47-DERb
cells with no ERb induction resulted in downregulation
of HER2 protein levels (Additional files 2 and 3), indi-
cating that under our experimental conditions, ERa
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Figure 1 Estrogen receptor b expression decreases Akt signaling in breast cancer cells. (A) T47-DERb cells were treated for 1 day up to 7
days with 10 ng/mL (-ERb) or 0.01 ng/mL (+ERb) doxycycline in the presence or absence of 10 nM 2,3-bis(4-hydroxy-phenyl)-propionitrile (DPN).
(B) MCF-7ERb cells were treated for 4 days or 7 days with 10 ng/mL (-ERb) or 0.01 ng/mL (+ERb) doxycycline in the presence or absence of 10
nM DPN. (C) T47-DPBI control cells were treated for 4 days with 10 ng/mL or 0.01 ng/mL doxycycline, in the presence or absence of 10 nM
DPN. (D and E) T47-DERb cells were treated for 4 days with 10 ng/mL (-ERb) or 0.01 ng/mL (+ERb) doxycycline in the presence or absence of
(D) 10 nM DPN with or without 100 nM ICI 182, 789 (ICI) or (E) 100 nM 4-hydroxy-tamoxifen (4-OH-T). For Figures 1A to 1E, cell lysates were
analyzed by immunoblotting. In Figure 1A, the estrogen receptor b (ERb) antibody used was 14021 from Abcam. In Figures 1B, 1D and 1E, the
ERb antibody was GTX110607 from GeneTex. This antibody produced a nonspecific band above the ERb band.
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ERb upregulation of HER2 could be related to reduced
ERa action by the formation of ERa/ERb heterodimers,
which relieves ERa homodimer-mediated repression of
HER2 expression, and/or by ERb repressing the expres-
sion of ERa, as seen in our cell models. Exposure of
T47-DERb cells to the ER antagonists ICI or 4-OH-T
enhanced HER2 mRNA and protein levels, an effect that
could be due to removal of the ERa-PAX2 repressive
effect on HER2 gene expression. Interestingly, when ICI
or 4-OH-T was added to ERb expressing cells, ERb
changed from being an inducer to a repressor of HER2
mRNA and protein expression. In our cell model, expo-
sure to ICI resulted in the disappearance of ERa protein
and a marked increase of HER2. Thus, in ICI-treated
cells expressing ERb, it is likely that an ERb homodimer
is acting as a repressor of HER2 gene expression.
Furthermore, 4-OH-T treatment also shifted ERb from
being an activator to being a repressor. This could per-
haps be explained by 4-OH-T having an antagonistic
action on ERa but not on ERb, a possible scenario if
both receptors are activated ligand-independently by
phosphorylation, where ERb is less sensitive to antagon-
ism from 4-OH-T [49]. It is clear that further studies
with T47-DERb cells are needed to better understand
the mechanisms by which ERb regulates HER2 expres-
sion, including determination of PAX2 and SRC-3 levels
under different experimental conditions.
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downregulation of HER3 protein levels (Figure 3B).
qRT-PCR analysis showed that ICI and 4-OH-T both
increased overall HER3 mRNA levels, which could be
indicative of ERa, similarly to ERb, having a repressive
effect on HER3 mRNA expression. However, the ERa-
selective ligand PPT had no effect on HER3 protein
expression. Further studies are needed to explain this
difference. ICI, but not 4-OH-T, clearly did not inhibit
ERb-induced downregulation of HER3 mRNA. The ICI-
induced increase and ERb-induced downregulation of
HER3 mRNA levels in ICI-treated cells correlated well
with HER3 protein levels. This was not obvious in 4-
OH-T treated cells, where a difference was seen at the
protein level but not at the mRNA level.
ERb downregulates heregulin-induced activation of HER2/
HER3 dimer and Akt
Heregulin-b1( H R G - b1), a member of the EGFR family,
is a ligand for HER3. As HER3 has no intracellular tyro-
sine kinase domain, it partners with other members of
the EGFR family to initiate intracellular signaling. The
preferred dimerization partner is HER2, which has tyro-
sine kinase activity. In the intracellular domain of HER3,
there are six tyrosines that, upon phosphorylation by
HER2, will serve as docking sites for the p85 adaptor
subunit of PI3K. Thus, HRG-b1 activation of the HER2/
HER3 dimer results in strong activation of the PI3K/Akt
signaling pathway.
To elucidate whether ERb could influence HRG-b1
activation of the HER2/HER3 and Akt pathways, T47-
DERb cells were cultured for 4 days with or without
ERb expression and in the absence or presence of DPN,
whereafter HRG-b1 was added for 30 minutes. The
addition of HRG-b1 to T47-DERb cells clearly induced
phosphorylation of HER2, HER3 and Akt (Figure 4A).
ERb decreased levels of phosphorylated HER3 (Figure
4A). This effect probably could be explained by the
ERb-induced downregulation of HER3 protein (Figures
2A, D, 3B and 4A). Interestingly, even though ERb upre-
gulated HER2 protein levels (Figures 2A, C, 3A and 4A),
ERb decreased HRG-b1-induced HER2 phosphorylation,
also possibly due to ERb-induced decrease of the HER2
dimerization partner HER3.
Exposure of T47-DERb cells to HRG-b1f o r3 0m i n -
utes also dramatically increased levels of pAkt (Figure
4A). At this time point, ERb expression did not decrease
levels of phosphorylated Akt. However, a time study of
HRG-b1-stimulated cells showed that from 2 hours
onward, ERb presence decreased levels of phosphory-
lated Akt (Figure 4B). One possible explanation for this
could be that in the acute phase after HRG-b1 addition,
there was a massive activation of Akt due to the already
mutated PIK3CA in T47-DERb cells, an activation that
ERb could not inhibit. However, ERb could decrease
levels of phosphorylated Akt after its peak activity, when
the activity was still clearly above that in unstimulated
cells (Figure 4A).
Exposure of cells to DPN, E2 or WAY (another ERb
selective agonist) did not influence levels of HRG-b1-
induced phosphorylated HER2, HER3 and Akt (Figure
4A andAdditional file 3). To further investigate the Akt
pathway in the context of endocrine sensitivity and ERb
expression, in addition to HRG-b1 treatment, cells were
further treated with ICI or 4-OH-T (Figure 4A). ICI and
4-OH-T exposure both increased levels of phosphory-
lated HER2 and HER3 in the absence or presence of
ERb. An effect that may be related to increased total
HER2 levels in cells treated with ICI or 4-OH-T (Fig-
ures 3A and 4A). However, levels of phosphorylated
HER2 and pHER3 were clearly lower when ERb was
present.
PTEN levels increase following ERb expression
PTEN mediates its main tumor-suppressive function
through dephosphorylation of PIP3. Interestingly, in a
recent report [50], it was shown that in mice with a
subtle reduction of PTEN expression (80% of the nor-
mal level), different types of tumors developed with
mammary carcinomas occurring at highest penetrance.
Also, reduced levels or loss of PTEN has been impli-
c a t e di nt h ed e v e l o p m e n to fe n d o c r i n er e s i s t a n c ei n
breast cancer. Since PTEN is an important regulator of
Akt signaling, we found it important to investigate the
effect of ERb on PTEN expression. ERb expression
upregulated PTEN levels in both T47-DERb and MCF-
7ERb cells (Figure 5A). DPN, E2 or WAY addition did
not further upregulate PTEN levels (Figure 5A and
Additional file 4). No significant changes were seen in
the control cell line (T47-DPBI) under the same condi-
tions (Figure 5A). Thus, the ERb effect on PTEN levels
was seen not only in one breast cancer cell type and
was not due to doxycycline. The T47-DERb cells expres-
sing ERb or not were also analyzed using PTEN immu-
nofluorescence. As shown in Figure 5B, PTEN protein
levels were clearly upregulated in ERb-expressing cells.
Exposure of T47-DERb cells to ICI or 4-OH-T did not
decrease or inhibit the ERb effect on PTEN protein
levels (Figure 5C and Additional file 5). The effect of
ERb expression on PTEN mRNA levels was also investi-
gated. However, no conclusive data could be obtained
from these experiments (data not shown). One explana-
tion for the observed effects of ERb on PTEN protein
levels could be that ERb regulates expression of other
proteins that in turn regulate PTEN. Further studies are
needed to clarify this hypothesis.
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tamoxifen
PTEN downregulation as well as increased HER2/HER3
and Akt signaling have been associated with endocrine
resistance in breast tumors. With our above-described
results in mind, we found it imperative to investigate
whether expression of ERb would increase the sensitivity
to tamoxifen in T47-DERb and MCF-7ERb breast can-
cer cells. Experiments were performed in cells where
ERb was expressed for 4 days in the absence or presence
of the agonists E2 and WAY, whereafter 1,000 nM
tamoxifen was added for either 5 days (T47-DERb)o r7
days (MCF-7ERb). The selective agonist DPN was not
used in these experiments because of our previous
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Figure 4 Effect of ERb on heregulin-b1-activated HER2, HER3 and Akt. (A) T47-DERb cells were treated for 4 days with 10 ng/mL (-ERb)o r
0.01 ng/mL (+ERb) doxycycline in the presence or absence of 10 nM DPN with or without 100 nM ICI or 100 nM 4-OH-T and stimulated with
heregulin-b1 (HRG-b1) for 30 minutes. (B) T47-DERb cells were treated as described above and stimulated with HRG-b1 for 30 minutes up to 24
hours. Lysates were analyzed by immunoblotting.
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Page 9 of 13findings that, besides inhibiting proliferation, DPN also
seems to affect this kind of viability assay, depending on
metabolism [51]. Instead, the selective ERb ligand WAY
was used, which did not influence the assay. In both cell
lines, and in the absence of ERb, 4-OH-T decreased
growth (Figure 6). In MCF-7ERb cells, we observed a
more marked effect, which could be due to less active
Akt signaling (Additional file 1). In MCF-7ERb cells, but
not in T47-DERb cells, E2 also slightly counteracted the
effect of 4-OH-T. Expression of ERb alone clearly
reduced growth in both cell lines. This was further sig-
nificantly enhanced with exposure to WAY in ERb-
expressing T47-DERb cells. In MCF-7ERb cells, a slight
enhancement of growth reduction was also seen with
WAY treatment, but it did not reach significance.
Expression of ERb, together with exposure to 4-OH-T,
significantly further decreased cell growth as compared
to growth seen in only ERb-expressing cells. Similar
results were seen in both cell lines with 500 nM
tamoxifen (results not shown). In summary, these results
show that ERb expression render ERa-expressing breast
cancer cells more sensitive to tamoxifen treatment.
In several experiments, the addition of agonist or
antagonist did not increase or decrease the effect of ERb
expression on its own. This could indicate that in these
breast tumor cells, ERb is activated in a ligand-indepen-
dent manner; for example, it is phosphorylated in the
AF-1 domain and then is also less inhibited by antago-
nists that have a focus on ligand-binding and the AF-2
domain [49]. Further studies are needed to clarify this
hypothesis with mapping of phosphorylated sites of ERb
in these cells. Interestingly, a recent report [52] shows
that ERb phosphorylated at serine 105 is associated with
a good prognosis in breast cancer. A future challenge is
to develop ligands that, in this setting, that is, ERb-
expressing breast cancers with increased kinase activity,
could activate or increase the inhibitory effect of ERb on
Akt signaling.
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Figure 5 PTEN levels increase upon ERb expression. (A) T47-DERb cells, MCF-7ERb cells and T47-DPBI control cells were treated for 4 days
with 10 ng/mL or 0.01 ng/mL doxycycline in the presence or absence of 10 nM DPN, and lysates were analyzed by immunoblotting. (B)
Phosphatase and tensin homologue deleted on chromosome 10 (PTEN) immunofluorescence of T47-DERb cells treated for 4 days with 10 ng/
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Our results suggest a link between expression of ERb
and endocrine sensitivity by increasing PTEN levels and
decreasing HER2/HER3 signaling, thereby reducing Akt
signaling with subsequent effects on proliferation, survi-
val and tamoxifen sensitivity of breast cancer cells. This
study supports initiatives to further investigate whether
ERb presence in breast cancer samples is an indicator
for endocrine response. Current therapies in ERa-posi-
tive breast cancers aim to impair ERa activity with
antagonists or by removal of endogenous estrogens with
aromatase inhibitors. Data from this study could be
taken as indicative for using ERb as a target in selected
groups of breast cancer.
Additional material
Additional file 1: Western blot analysis of Akt signaling in T47D and
MCF-7 cells. T47-DERb and MCF-7ERb cells were treated for 4 days with
10 ng/mL (-ERb) or 0.01 ng/mL (+ERb) doxycycline in the presence or
absence of 10 nM 2,3-bis(4-hydroxy-phenyl)-propionitrile (DPN). Lysates
were analyzed by immunoblotting. ERb, estrogen receptor b.
Additional file 2: Effects of the ERa-selective ligand PPT on
expression of HER2 and HER3. T47-DERb cells were treated for 4 days
with 10 ng/mL (-ERb) or 0.01 ng/mL (+ERb) doxycycline, in the presence
or absence of 10 nM 4,4¶,400-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol
(PPT). Lysates were analyzed by immunoblotting.
Additional file 3: Influence of different ER ligands on ERb effects on
HRG-b1-stimulated signaling. T47-DERb cells were treated for 4 days
with 10 ng/mL (-ERb) or 0.01 ng/mL (+ERb) doxycycline in the presence
or absence of 10 nM DPN, 10 nM 7-bromo-2-(4-hydroxyphenyl)-1,3-
benzoxazol-5-ol (WAY) or 10 nM 17b-estradiol (E2) and thereafter were
stimulated for 30 minutes with 10 ng/mL heregulin-b1 (HRG-b1). Lysates
were analyzed by immunoblotting.
Additional file 4: ERb effects on PTEN protein expression using
different ER selective ligands. T47-DERb cells were treated for 4 days
with 10 ng/mL (-ERb) or 0.01 ng/mL (+ERb) doxycycline in the presence
or absence of 10 nM DPN, 10 nM WAY or 10 nM E2. Lysates were
analyzed by immunoblotting. PTEN, phosphatase and tensin homologue
deleted on chromosome 10.
Additional file 5: Influence of ER antagonists on ERb effects on
PTEN protein expression. T47-DERb cells were treated for 4 days with
10 ng/mL (-ERb) or 0.01 ng/mL (+ERb) doxycycline in the presence or
absence of 10 nM DPN, 100 nM 4-OH-T or 100 nM ICI 182, 789 (ICI).
Lysates were analyzed by immunoblotting. Densitometric scanning of
three immunoblots is shown.
Abbreviations
DPN: 2,3-bis(4-hydroxy-phenyl)-propionitrile; EGFR: epidermal growth factor
receptor; ER: estrogen receptor; E2: 17β-estradiol; HER2 proto-oncogene c-
ErbB-2; HER3: receptor tyrosine kinase erbB-3; HRG-β1: heregulin-β1; ICI: ICI
182: 789; 4-OH-T: 4-hydroxy-tamoxifen; PCR: polymerase chain reaction; PI3K:
phosphatidylinositol 3-kinase; PIP3: phosphatidylinositol (3,4,5)-triphosphate;
PPT: 4,4’,4"-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol; PTEN: phosphatase
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bromo-2-(4-hydroxyphenyl)-1,3-benzoxazol-5-ol.
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Figure 6 ERb improves sensitivity to tamoxifen in breast cancer cells.T 4 7 - D E R b cells and MCF-7ERb cells were treated for 5 and 7 days,
respectively, with 10 ng/mL (-ERb) or 0.01 ng/mL (+ERb) doxycycline in the presence or absence of 10 nM 7-bromo-2-(4-hydroxyphenyl)-1,3-
benzoxazol-5-ol (WAY) or 10 nM 17b-estradiol (E2). Thereafter cells were exposed to 1,000 nM 4-OH-T. At indicated time points, cell numbers
were measured using a WST-1 colorimetric assay as described in Materials and methods. Significant differences were analyzed using one-way
ANOVA and Tukey’s multiple posttest. *P < 0.05 vs. -ERb.* * P < 0.05 vs. +ERb.
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